311 related articles for article (PubMed ID: 33345323)
1. Persistent treatment resistance in genetic generalized epilepsy: A long-term outcome study in a tertiary epilepsy center.
Cerulli Irelli E; Morano A; Barone FA; Fisco G; Fanella M; Orlando B; Fattouch J; Manfredi M; Giallonardo AT; Di Bonaventura C
Epilepsia; 2020 Nov; 61(11):2452-2460. PubMed ID: 33345323
[TBL] [Abstract][Full Text] [Related]
2. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
[TBL] [Abstract][Full Text] [Related]
3. Generalized paroxysmal fast activity in EEG: An unrecognized finding in genetic generalized epilepsy.
Sagi V; Kim I; Bhatt AB; Sonmezturk H; Abou-Khalil BW; Arain AM
Epilepsy Behav; 2017 Nov; 76():101-104. PubMed ID: 28874317
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome in adolescent-onset generalized genetic epilepsies.
Vorderwülbecke BJ; Kowski AB; Kirschbaum A; Merkle H; Senf P; Janz D; Holtkamp M
Epilepsia; 2017 Jul; 58(7):1244-1250. PubMed ID: 28464258
[TBL] [Abstract][Full Text] [Related]
5. Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsies.
Gesche J; Khanevski M; Solberg C; Beier CP
Epilepsia; 2017 Apr; 58(4):e64-e69. PubMed ID: 28230254
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of adult patients with genetic generalized epilepsy with typical absence seizures and generalized paroxysmal fast activity in their EEG.
Aydin-Özemir Z; Matur Z; Bebek N; Gürses C; Gökyiğit A; Baykan B
Seizure; 2014 Sep; 23(8):607-15. PubMed ID: 24908140
[TBL] [Abstract][Full Text] [Related]
7. Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome.
Cerulli Irelli E; Morano A; Cocchi E; Casciato S; Fanella M; Albini M; Avorio F; Basili LM; Fisco G; Barone FA; Mascia A; D'Aniello A; Manfredi M; Fattouch J; Quarato P; Giallonardo AT; Di Gennaro G; Di Bonaventura C
Epilepsia; 2020 Jan; 61(1):107-114. PubMed ID: 31828782
[TBL] [Abstract][Full Text] [Related]
8. Electroclinical aspects and therapy of Han patients with juvenile myoclonic epilepsy in northern China.
Wang L; Jiang Z; Chen BB; Wang CT; Wang JX; Bai J; Wang B; Jin L; Zhang WJ; Deng YC; Zhao G; Dang JX; Wang D; Jia SS; Wang TC; Jia FY; Zhang L; Liu YH
Epilepsy Behav; 2016 Sep; 62():204-8. PubMed ID: 27494356
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of higher drug load for seizure freedom in idiopathic generalized epilepsy: Comparison between juvenile myoclonic epilepsy and other types.
Kitazawa Y; Jin K; Kakisaka Y; Fujikawa M; Tanaka F; Nakasato N
Epilepsy Res; 2018 Aug; 144():20-24. PubMed ID: 29729533
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M
Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
[TBL] [Abstract][Full Text] [Related]
13. Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.
Welty TE
Paediatr Drugs; 2006; 8(5):303-10. PubMed ID: 17037947
[TBL] [Abstract][Full Text] [Related]
14. Generalized Fast Discharges Along the Genetic Generalized Epilepsy Spectrum: Clinical and Prognostic Significance.
Cerulli Irelli E; Barone FA; Mari L; Morano A; Orlando B; Salamone EM; Marchi A; Fanella M; Fattouch J; Placidi F; Giallonardo AT; Izzi F; Di Bonaventura C
Front Neurol; 2022; 13():844674. PubMed ID: 35356452
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.
Tabrizi N; Zarvani A; Rezaei P; Cheraghmakani H; Alizadeh-Navaei R
Epilepsy Res; 2019 Nov; 157():106214. PubMed ID: 31627041
[TBL] [Abstract][Full Text] [Related]
16. Seizure outcome trajectories in a well-defined cohort of newly diagnosed juvenile myoclonic epilepsy patients.
Cerulli Irelli E; Morano A; Orlando B; Salamone EM; Fanella M; Fattouch J; Manfredi M; Giallonardo AT; Di Bonaventura C
Acta Neurol Scand; 2022 Mar; 145(3):314-321. PubMed ID: 34791656
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with refractory idiopathic generalized epilepsy.
Gomez-Ibañez A; McLachlan RS; Mirsattari SM; Diosy DC; Burneo JG
Epilepsy Res; 2017 Feb; 130():69-73. PubMed ID: 28157601
[TBL] [Abstract][Full Text] [Related]
18. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate.
Calleja S; Salas-Puig J; Ribacoba R; Lahoz CH
Seizure; 2001 Sep; 10(6):424-7. PubMed ID: 11700996
[TBL] [Abstract][Full Text] [Related]
19. High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: Going from low to high.
Hernández-Vanegas LE; Jara-Prado A; Ochoa A; Rodríguez Y Rodríguez N; Durón RM; Crail-Meléndez D; Alonso ME; Delgado-Escueta AV; Martínez-Juárez IE
Epilepsy Behav; 2016 Aug; 61():34-40. PubMed ID: 27300146
[TBL] [Abstract][Full Text] [Related]
20. Reconsidering the role of selective sodium channel blockers in genetic generalized epilepsy.
Cerulli Irelli E; Morano A; Fanella M; Orlando B; Salamone EM; Giallonardo AT; Di Bonaventura C
Acta Neurol Scand; 2021 Dec; 144(6):647-654. PubMed ID: 34314016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
